Recursion Pharmaceuticals (RXRX) Accumulated Depreciation & Amortization (2022 - 2025)
Recursion Pharmaceuticals (RXRX) has disclosed Accumulated Depreciation & Amortization for 4 consecutive years, with $83.7 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 129.36% year-over-year to $83.7 million, compared with a TTM value of $83.7 million through Dec 2025, up 129.36%, and an annual FY2025 reading of $83.7 million, up 129.36% over the prior year.
- Accumulated Depreciation & Amortization was $83.7 million for Q4 2025 at Recursion Pharmaceuticals, up from $36.5 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $83.7 million in Q4 2025 and bottomed at $2.8 million in Q1 2022.
- Average Accumulated Depreciation & Amortization over 4 years is $21.5 million, with a median of $16.3 million recorded in 2024.
- The sharpest move saw Accumulated Depreciation & Amortization surged 34.73% in 2023, then soared 129.36% in 2025.
- Year by year, Accumulated Depreciation & Amortization stood at $11.8 million in 2022, then skyrocketed by 107.57% to $24.4 million in 2023, then skyrocketed by 49.55% to $36.5 million in 2024, then soared by 129.36% to $83.7 million in 2025.
- Business Quant data shows Accumulated Depreciation & Amortization for RXRX at $83.7 million in Q4 2025, $36.5 million in Q4 2024, and $23.5 million in Q3 2024.